FDA Approves BridgeBio Affiliate's Therapy for Rare Metabolic Disease
Published: Mar 01, 2021 By Brandon May Rafael Henrique/SOPA Images/LightRocket via Getty Images The U.S. Food and Drug Administration (FDA) has approved BridgeBio Pharma and its affiliate Origin Biosciences’ injectable, rare genetic metabolic disorder therapy NULIBRY™ (fosdenopterin). This approval marks the first treatment indicated for reducing mortality risk in patients with the rare disorder known as molybdenum cofactor deficiency (MoCD) Type A. An ultra-rare and progressive disease, MoCD Type A affects fewer than 150 patients across the globe. Overall, the median survival fo...
Source: biospace.com